Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV

By sjmartinez • April 9, 2025

Daar ES, Orkin C, Sax PE, Hagins D, Pozniak A, Workowski K, Brinson C, Tiraboschi JM, Liu H, Deaton C, Cohen C, Madera S, Hindman JT, Ramgopal M. Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV. AIDS Res Ther. 2025 Apr 7;22(1):45. doi: 10.1186/s12981-025-00732-w. PMID: 40197415; PMCID: PMC11978100.

Tags: antiretroviral therapy, Bictegravir, body mass index, dolutegravir, glucose, Harbor UCLA, HIV-1, Infectious Diseases, Publications, Tenofovir alafenamide

Multifactorial causes of severe persistent hypercalcemia in an immunosuppressed woman with chronic kidney disease

Nalluri K, Goodman EL, Pasupneti T, Nunez G, Wang EC. Multifactorial causes of severe persistent hypercalcemia in an immunosuppressed woman with chronic kidney disease. JCEM[...]

Effects of normobaric hypoxia and hyperthermia on ventilatory responses to high-intensity interval training bouts

Girardi M, Nicolò A, Marcora SM, Bazzucchi I, Felici F, Dickinson J, Sacchetti M. Effects of normobaric hypoxia and hyperthermia on ventilatory responses to high-intensity[...]

Agatston-2.0: A next-generation AI-based coronary calcium quantification approach to improve risk stratification among individuals with zero Agatston scores – Part I: An AI-CVD Study within the Multi-Ethnic Study of Atherosclerosis and Framingham Heart Study

Naghavi M, Azimi A, Atlas K, Reeves AP, Zhang C, Mirjalili SR, Mozafarybazargany M, Jolfayi AG, Hashemi A, Atlas T, Wasserthal J, Vliegenthart R, Henschke[...]